Biogen (BIIB) shows a bullish trend with new investments and milestones achieved for their Zorevunersen and BIIB142 Pipeline. Several major asset management firms like
Fred Alger Management LLC and Alliancebernstein L.P. increased their stake in the company. Biogen's share value has seen a significant rise after
At-Home Alzheimer’s Therapy data updates and FDA's approval for their home-based treatments -
Leqembi and Dravet therapy.
Biogen also reported positive Q2 earnings, beating the estimated metrics, and raised their outlook for 2025. The company is moving toward a
$2B manufacturing investment in North Carolina's Research Triangle Park. Notably, the
FDA has approved their Alzheimer's drug, Leqembi, and their Tau-Targeting Therapy,
BIIB080, received Fast Track Designation for Alzheimer's treatment.
Additional notable investments and new positions have been made by Evergreen Capital Management LLC and others, indicating strong market confidence. Despite cutting some shares, the
Royal Bank of Canada still holds a significant stake worth $45.23 Million. The company's partnership with Eisai and the subsequent approval for the Alzheimer's treatment further strenghtens its market position.
Biogen BIIB News Analytics from Wed, 02 Apr 2025 07:00:00 GMT to Sun, 14 Sep 2025 00:57:49 GMT -
Innovation 8
- Rumor -8
